Han XL 2007.

Methods	Country: China Setting: outpatients and inpatients Aim: to explore the effect of Shugan Zishen Huoxue tang on postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T‐test, Chi2 test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 42 postmenopausal osteoporosis patients enrolled: 25 in herb trial group, 17 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: endocrine diseases, etc.
Interventions	Experimental: Shugan Zishen Huoxue tang (100 ml, twice a day), Caltrate (1.2 g, twice a day) and alendronate sodium (10 mg, once a day), for 6 months Control: Caltrate (1.2 g, twice a day) and alendronate sodium tablets (10 mg, once a day), for 6 months
Outcomes	BMD, E2
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias